May is Asian American and Pacific Islander (AAPI) Heritage Month, an annual celebration that recognizes the historical and cultural contributions of individuals and groups of Asian and Pacific Islander descent to the United States. #AAPIHeritageMonth
Neurocrine Biosciences
Biotechnology Research
San Diego, California 55,856 followers
You Deserve Brave Science
About us
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, Parkinson’s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. Review our Community Guidelines: https://bit.ly/3L8M8hx *in collaboration with AbbVie
- Website
-
http://www.neurocrine.com
External link for Neurocrine Biosciences
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 1992
- Specialties
- Movement Disorders, CNS, Neurology, and Endocrinology
Locations
-
Primary
San Diego, California, US
-
12780 El Camino Real
San Diego, CA 92130, US
Employees at Neurocrine Biosciences
-
Matt Crawford, MBA
Regional Specialty Manager - Long Term Care at Neurocrine Biosciences
-
Annette Dowsing
-
Hector Ortega
Award-Winning Key Account Manager | I Help Biopharma Engage High Value Customers: C-Suite, HCPs, IDNs, KOLs | Boost Market Share, Drive Sales…
-
Lori Hodsoll, PACS
Regional Patient Access Manager
Updates
-
HD Reach works to improve the care and quality of life for those affected by Huntington’s disease (HD). #HDAwarenessMonth is a time to shine a light on the HD community. This month, HD Reach will highlight their ongoing efforts to provide connections to medical providers, care management, family support and education. Learn more: hdreach.org
-
Neurocrine Biosciences reposted this
I’m excited to share that I have been named Neurocrine Biosciences’ next CEO. For the Board to entrust me to lead Neurocrine is an incredible honor and opportunity. I’m eager to work alongside each of my colleagues to keep advancing our Purpose – to relieve suffering for people with great needs, but few options. I know our future is bright, because we have compelling science, a clear vision, and a world-class team. That foundation is a testament to my mentor Kevin Gorman – without whom, Neurocrine wouldn’t be Neurocrine. I know each of us is committed to building on our momentum and his legacy. Congratulations on a well-earned retirement.
-
Today we announced that after more than 30 years at Neurocrine Biosciences, Founder and CEO Kevin Gorman, Ph.D., is retiring, effective October 11, 2024. Under his leadership, Neurocrine has emerged as a fully integrated biopharmaceutical company with a highly successful commercial product and a broad, mature pipeline that includes 17 clinical development programs focused on helping patients across neurology, neuroendocrinology, and neuropsychology. Dr. Gorman has well-positioned Neurocrine to advance our Purpose – to relieve suffering for people with great needs, but few options. Dr. Gorman will continue to serve on the Board of Directors. We also announced that the Board of Directors has appointed Kyle W. Gano Gano, Ph.D., Neurocrine’s Chief Business Development and Strategy Officer, as our next CEO and as a member of our Board of Directors, with both appointments effective upon Kevin’s retirement. Dr. Gano is a proven executive who joined Neurocrine more than 23 years ago. He is ideally suited to lead our Company’s next chapter of growth. With the foundation of a world-class team, compelling science, and clear vision, the Board and Dr. Gorman have tremendous confidence in Dr. Gano’s ability to continue executing Neurocrine’s strategy and lead the company into an exciting future. Read more about the announcement: https://lnkd.in/gpNEKdyK
-
We were proud to support Meadows Mental Health Policy Institute in hosting a Capitol Hill Briefing on May 22, in Washington D.C. The Meadows Institute was joined by National Council for Mental Wellbeing and Alliance for Patient Access to brief congressional staff and media on the findings and recommendations of the report "Increasing Measurement-Based Assessment and Care for People with Serious Mental Illness.” Read a full recap of the Briefing on the Meadows Institute’s website: https://lnkd.in/gbZsaWtg
-
This #HDAwarenessMonth, we are proud to launch More Than HD, a new educational website established to provide additional support to the HD community. More Than HD provides information to help individuals navigate their experiences living with #HuntingtonsDisease and Huntington’s disease chorea. Explore the site to learn more about the symptoms & stages of HD, symptom management, and building community. https://lnkd.in/gam6KEqz
-
The Meadows Mental Health Policy Institute recently released a report, in collaboration with Neurocrine Biosciences, highlighting the importance of measurement-based care for people with a serious mental illness who are treated with antipsychotics. Measurement-based care provides an effective mechanism for routine monitoring and earlier detection of medication-induced movement disorders, such as tardive dyskinesia (TD), to help improve outcomes. Access the full report: https://lnkd.in/dAf_MgVd #Screen4TD
-
Help 4 HD 's mission is to educate the world about Huntington’s disease (HD) every day and especially during #HDAwarenessMonth. Follow @Help4HDI as they spotlight HD awareness and education through the stories of HD families. #LetsTalkAboutHD
-
"Patients and family members feel that it’s stigmatizing to have the cognitive impairment of #schizophrenia pointed out to them. That’s not the stigmatizing part. That’s a part of the illness. I think the stigmatizing part is to say ‘well, there’s nothing that we can do about this.’” Watch Dr. Jean-Pierre Lindenmayer and Dr. Richard Keefe discuss cognitive challenges patients with schizophrenia face and the impact it has on their day-to-day lives.
-
The Huntington's Disease Youth Organization (HDYO) is an international non-profit supporting, educating, and empowering young people impacted by Huntington’s disease (HD). HDYO’s Ambassadors are a group of young people who share their experiences and aim to connect the HD community. Follow along during #HDAwarenessMonth at @HDYOFeed and hdyo.org and #LetsTalkAboutHD.